Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cristina Molina
Institution:
Vall d'Hebron Institute of Oncology
Observed institutions:
Universitat Autònoma de Barcelona,
Vall d'Hebron Institute of Oncology
ORCID:
0000-0003-1547-8528
Observed ORCID:
0000-0003-1547-8528
OpenAlex ID:
A5047129555
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2022
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
·
Clinical Cancer Research
·
26
PDF
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts
2025
·
Andreu Òdena
, Laia Monserrat
, et al.
·
npj Precision Oncology
·
1
PDF
Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer
2026
·
Laia Monserrat
, Judith García-García
, et al.
·
npj Breast Cancer
PDF
Supplementary Figure S6 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
PDF
Supplementary Table S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Table S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Table S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Table S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Figure S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Figure S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
PDF
Supplementary Figure S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Figure S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
PDF
Supplementary Figure S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2025
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Abstract LB_C04: Novel orally bioavailable macrocycles that target cyclin A and B elicit antitumor activity in breast cancer patient-derived xenograft models
2023
·
Mariana Paes Dias
, Li-Fen Liu
, et al.
·
Molecular Cancer Therapeutics
Supplementary Table S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Figure S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
PDF
Supplementary Figure S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
PDF
Supplementary Table S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Figure S6 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
PDF
Supplementary Table S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Figure S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Table S2 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Figure S4 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Supplementary Table S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
2023
·
Queralt Serra-Camprubí
, Helena Verdaguer
, et al.
Show more works
View as search
Works count:
28
Citation count:
27
H-index:
1
I10-index:
1
Year
Topic
Type